Abstract
Introduction Chronic breathlessness occurs across many different diseases, independently of severity. Yet, despite being strongly linked to adverse outcomes, chronic breathlessness is generally not considered a stand-alone treatment target. Here we move focus from identifying the “best” measurement tool and use data-driven techniques to identify and confirm the stability of underlying features (factors) driving breathlessness across different cardiorespiratory diseases. Such frameworks could provide an opportunity to address the underlying mechanisms of breathlessness and over-come issues with co-morbidities, particularly when medical therapies have been optimised.
Methods Longitudinal study of questionnaire data on 182 participants with main diagnoses of asthma (21.4%), COPD (24.7%), heart failure (19.2%), idiopathic pulmonary fibrosis (18.7%), other interstitial lung disease (5.5%), and “other diagnoses” (8.8%) were entered into an exploratory factor analysis (EFA). Participants were stratified based on their EFA factor scores, allowing us to examine whether the breathlessness experience differed across disease diagnosis. We then examined model stability after six months and established through an iterative process the most compact, and therefore least burdensome assessment tool.
Results From the 25 input measures, 16 measures were retained for model validation. The resulting model contained four factors to which we assigned the following descriptive labels: body burden, 2) affect/mood, 3) breathing burden and 4) anger/frustration. Stratifying patients by their scores across the four factors revealed two groups corresponding to high and low burden. These were not found to be predictive of primary disease diagnosis and did remain stable after six months.
Conclusions We have identified four stable and disease-independent factors that seem to underlie the experience of breathlessness. We suggest that interventions may target factors within this framework to answer the question of whether they are also driving the experience itself.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr Pattinson was supported by the JABBS Foundation, the Dunhill Medical Trust, and the NIHR Biomedical Research Centre based at Oxford University Hospitals NHS Trust and The University of Oxford.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data for the main study which were used in this subsequent analysis was approved by the Regional Ethical Board at Lund University (DNr: 2016/16).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(sarah.finnegan{at}ndcn.ox.ac.uk)
(kyle.pattinson{at}nda.ox.ac.uk)
(josefin.sundh{at}oru.se)
(magnus.skold{at}ki.se)
(christer.janson{at}medsci.uu.se)
(anders.blomberg{at}umu.se)
(jacob.sandberg{at}gmail.com)
(pmekstrom{at}gmail.com)
Disclosures Dr. Pattinson is named as co-inventors on a provisional U.K. patent application titled “Use of cerebral nitric oxide donors in the assessment of the extent of brain dysfunction following injury. He has also acted as a consultant for Nektar Therapeutics. The work for Nektar has no bearing on the contents of this manuscript. Dr Pattinson was supported by the JABBS Foundation, the Dunhill Medical Trust, and the NIHR Biomedical Research Centre based at Oxford University Hospitals NHS Trust and The University of Oxford.
Dr Finnegan, Dr Sundh, Prof Janson, Prof Blomberg, Prof Sköld, Dr Sandberg and Dr. Ekström discloses no conflicts of interest relevant to this work.
Data Availability
The data used for this analysis are part of the longitudinal dataset reported as: Ekstrom, M., et al., Validation of the Swedish Multidimensional Dyspnea Profile (MDP) in outpatients with cardiorespiratory disease. BMJ Open Respiratory Research, 2019. 6(1): p. e000381
